scholarly article | Q13442814 |
P819 | ADS bibcode | 2015PNAS..112E.992F |
P356 | DOI | 10.1073/PNAS.1423669112 |
P932 | PMC publication ID | 4352796 |
P698 | PubMed publication ID | 25681373 |
P5875 | ResearchGate publication ID | 273900348 |
P50 | author | Robert Gallo | Q469904 |
Jennifer Schwartz | Q43193794 | ||
Hélène Le Buanec | Q55241388 | ||
Daniel Zagury | Q55241653 | ||
Timothy Fouts | Q55590587 | ||
David C. Montefiori | Q63302725 | ||
George K. Lewis | Q91710020 | ||
Anthony L DeVico | Q114780410 | ||
P2093 | author name string | Barbara K Felber | |
Celia C LaBranche | |||
George N Pavlakis | |||
Rong Xu | |||
Genoveffa Franchini | |||
Ranajit Pal | |||
Ilia J Prado | |||
John H Eldridge | |||
Kathryn L Bobb | |||
Kenneth Bagley | |||
Michael A Egan | |||
Monica Vaccari | |||
Robert J Zagursky | |||
Shari Gordon | |||
P2860 | cites work | Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges | Q24812967 |
HIV-1 envelope glycoprotein structure | Q27011248 | ||
Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding | Q27675486 | ||
Immune-correlates analysis of an HIV-1 vaccine efficacy trial | Q29617377 | ||
HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development. | Q30381447 | ||
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies | Q33614365 | ||
Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion | Q33849237 | ||
Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3) | Q33855093 | ||
Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant | Q33877513 | ||
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines | Q33911935 | ||
The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques | Q34124090 | ||
Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques | Q34154514 | ||
Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine | Q34339365 | ||
HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies | Q34477471 | ||
Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development | Q34480617 | ||
Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge | Q34574409 | ||
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells | Q34798580 | ||
The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses | Q35040673 | ||
Adjuvant activity of the catalytic A1 domain of cholera toxin for retroviral antigens delivered by GeneGun | Q35066456 | ||
Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen | Q35076961 | ||
An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum | Q35077677 | ||
Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys | Q35077793 | ||
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques | Q35101333 | ||
Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1. | Q35165404 | ||
The TRIM5{alpha} genotype of rhesus macaques affects acquisition of simian immunodeficiency virus SIVsmE660 infection after repeated limiting-dose intrarectal challenge | Q35192754 | ||
Immunology. Immune activation with HIV vaccines | Q35551760 | ||
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys | Q35729899 | ||
ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses | Q35802771 | ||
A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3. | Q35877501 | ||
Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens | Q36141515 | ||
Risk of immunodeficiency virus infection may increase with vaccine-induced immune response | Q36276637 | ||
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family | Q36363231 | ||
Antigenic conservation and immunogenicity of the HIV coreceptor binding site | Q36403587 | ||
Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma | Q36528782 | ||
Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production | Q36547664 | ||
DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge | Q36637349 | ||
IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production | Q36671364 | ||
Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaques | Q36759774 | ||
Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies | Q36760147 | ||
T follicular helper cell diversity and plasticity | Q36823844 | ||
Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock | Q36827377 | ||
Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting | Q36954239 | ||
CD4-induced epitopes in the HIV envelope glycoprotein, gp120. | Q37017799 | ||
Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys | Q37032170 | ||
Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. | Q37347813 | ||
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys | Q37355237 | ||
Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein | Q37511699 | ||
Qualitative and quantitative variables that affect the potency of Fc- mediated effector function in vitro and in vivo: considerations for passive immunization using non-neutralizing antibodies | Q38160068 | ||
Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype | Q39334333 | ||
Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex | Q39593524 | ||
Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines | Q40066120 | ||
Sequential evolution and escape from neutralization of simian immunodeficiency virus SIVsmE660 clones in rhesus macaques | Q41876895 | ||
Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate | Q42054413 | ||
Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention | Q42257677 | ||
A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques | Q43602552 | ||
A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoid | Q43618512 | ||
The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years | Q43818994 | ||
Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model | Q43897345 | ||
Fractionation, structural studies, and immunological characterization of the semi-synthetic Quillaja saponins derivative GPI-0100. | Q44551911 | ||
Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus | Q45428925 | ||
Immunogenicity of DNA vaccines that direct the coincident expression of the 120 kDa glycoprotein of human immunodeficiency virus and the catalytic domain of cholera toxin. | Q45722955 | ||
Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology | Q45743923 | ||
In vivo adaptation of SHIV(SF162): chimeric virus expressing a NSI, CCR5-specific envelope protein | Q45745791 | ||
HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. | Q51036136 | ||
Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. | Q51977322 | ||
A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. | Q52841139 | ||
Effectiveness of the quillaja saponin semi-synthetic analog GPI-0100 in potentiating mucosal and systemic responses to recombinant HagB from Porphyromonas gingivalis | Q54518119 | ||
Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251 | Q64378954 | ||
Molecular characterization of SIV in tissues from experimentally infected macaques | Q68589627 | ||
Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies | Q72146275 | ||
Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity | Q73902433 | ||
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation | Q79213173 | ||
A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques | Q80464237 | ||
Macaques co-immunized with SIVgag/pol-HIVenv and IL-12 plasmid have increased cellular responses | Q80720967 | ||
Interleukin-12 redirects murine immune responses to soluble or aluminum phosphate adsorbed HSV-2 glycoprotein D towards Th1 and CD4+ CTL responses | Q80973775 | ||
Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice | Q81157693 | ||
P2507 | corrigendum / erratum | Correction for Fouts et al., Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection | Q87132374 |
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Macaca | Q177601 |
P304 | page(s) | E992-9 | |
P577 | publication date | 2015-02-13 | |
P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
P1476 | title | Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection | |
P478 | volume | 112 |
Q29365310 | 2016 International meeting of the Global Virus Network |
Q26830360 | A New Scientific Paradigm may be Needed to Finally Develop an HIV Vaccine |
Q40748041 | An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques |
Q38539513 | Antibodies as a source of anti-infective peptides: an update |
Q64071431 | Antibody Fab-Fc properties outperform titer in predictive models of SIV vaccine-induced protection |
Q39189458 | Antibody Functional Assays as Measures of Fc Receptor-Mediated Immunity to HIV - New Technologies and their Impact on the HIV Vaccine Field |
Q92538619 | Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway |
Q59352288 | Antibody-dependent cellular cytotoxicity in HIV infection |
Q90000438 | Antibody-dependent cellular cytotoxicity targeting CD4-inducible epitopes predicts mortality in HIV-infected infants |
Q54263363 | Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cell-mediated cytotoxicity assay. |
Q37497214 | Biophysical and Functional Characterization of Rhesus Macaque IgG Subclasses. |
Q37261545 | Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition |
Q28084474 | Boosting vaccine efficacy the natural (killer) way |
Q36008380 | Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses |
Q92177871 | Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models |
Q90384404 | Calcium Phosphate Nanoparticle-Based Vaccines as a Platform for Improvement of HIV-1 Env Antibody Responses by Intrastructural Help |
Q35913921 | Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1 |
Q55154648 | Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity. |
Q26782237 | Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1 |
Q58120027 | Correlates of GLA family adjuvants' activities |
Q53692345 | Correlates of Protection Against SIVmac251 Infection in Rhesus Macaques Immunized With Chimpanzee-Derived Adenovirus Vectors. |
Q92019600 | Current advances in HIV vaccine preclinical studies using Macaque models |
Q55493835 | DNA immunization site determines the level of gene expression and the magnitude, but not the type of the induced immune response. |
Q36071896 | Developing a Successful HIV Vaccine |
Q38717198 | Engineering broadly neutralizing antibodies for HIV prevention and therapy |
Q38827936 | Enhancing the Quality of Antibodies to HIV-1 Envelope by GagPol-Specific Th Cells |
Q40040813 | Formulation of chitosan with the polyepitope HIV-1 protein candidate vaccine efficiently boosts cellular immune responses in mice |
Q95323134 | Glycopeptide epitope facilitates HIV-1 envelope specific humoral immune responses by eliciting T cell help |
Q56523156 | HIV vaccine candidate activation of hypoxia and the inflammasome in CD14 monocytes is associated with a decreased risk of SIV acquisition |
Q41918753 | HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine |
Q36323975 | HIV-1 gp120 envelope glycoprotein determinants for cytokine burst in human monocytes. |
Q40339467 | HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Speci |
Q59354714 | HIV/AIDS Vaccines: 2018 |
Q26766153 | Harnessing the protective potential of HIV-1 neutralizing antibodies |
Q55022148 | High-resolution definition of humoral immune response correlates of effective immunity against HIV. |
Q47215816 | Human immunodeficiency virus type-1 (HIV-1) evades antibody-dependent phagocytosis. |
Q37523341 | Humoral Antibody Responses to HIV Viral Proteins and to CD4 Among HIV Controllers, Rapid and Typical Progressors in an HIV-Positive Patient Cohort. |
Q64234945 | Identification of HIV gp41-specific antibodies that mediate killing of infected cells |
Q59357079 | Immune Correlate-Guided HIV Vaccine Design |
Q40071705 | Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models |
Q98196674 | Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature |
Q37399606 | Impaired T Cell-dependent Humoral Immune Response Associated with Juvenile-onset Recurrent Respiratory Papillomatosis Progression |
Q47110966 | Increasing the Clinical Potential and Applications of Anti-HIV Antibodies |
Q64084496 | Induction of Fc-Mediated Effector Functions Against a Stabilized Inner Domain of HIV-1 gp120 Designed to Selectively Harbor the A32 Epitope Region |
Q64263004 | Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1 |
Q64066666 | Mind the Gap: How Interspecies Variability in IgG and Its Receptors May Complicate Comparisons of Human and Non-human Primate Effector Function |
Q92340123 | Modulation of the CCR5 Receptor/Ligand Axis by Seminal Plasma and the Utility of In Vitro versus In Vivo Models |
Q104486611 | Mucosal IL-4R antagonist HIV vaccination with SOSIP-gp140 booster can induce high-quality cytotoxic CD4+/CD8+ T cells and humoral responses in macaques |
Q64115950 | Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response |
Q64268432 | Myeloid Cell Crosstalk Regulates the Efficacy of the DNA/ALVAC/gp120 HIV Vaccine Candidate |
Q38652858 | Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo |
Q47112156 | Novel Concepts for HIV Vaccine Vector Design |
Q40730039 | Paring Down HIV Env: Design and Crystal Structure of a Stabilized Inner Domain of HIV-1 gp120 Displaying a Major ADCC Target of the A32 Region |
Q39305961 | Pathogenic infection of Rhesus macaques by an evolving SIV-HIV derived from CCR5-using envelope genes of acute HIV-1 infections |
Q47109778 | Patterns of conserved gp120 epitope presentation on attached HIV-1 virions |
Q37718399 | Peripheral blood lymphocyte subset levels differ in patients with hepatocellular carcinoma. |
Q33821896 | Probing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition |
Q34540352 | Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response. |
Q92288781 | Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector |
Q91276841 | Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV |
Q36523998 | Signatures in Simian Immunodeficiency Virus SIVsmE660 Envelope gp120 Are Associated with Mucosal Transmission but Not Vaccination Breakthrough in Rhesus Macaques |
Q36708266 | Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine |
Q61816156 | Structural Basis for Epitopes in the gp120 Cluster A Region that Invokes Potent Effector Cell Activity |
Q30238730 | Survivors Remorse: antibody-mediated protection against HIV-1. |
Q30238729 | Systems serology for evaluation of HIV vaccine trials |
Q47604797 | Targeting the Late Stage of HIV-1 Entry for Antibody-Dependent Cellular Cytotoxicity: Structural Basis for Env Epitopes in the C11 Region. |
Q64060305 | The Antibodiome-Mapping the Humoral Immune Response to HIV |
Q42723888 | The Toughest Nut to Crack: Will We Ever Have a Preventive and Effective HIV-1 Vaccine? |
Q37113972 | The role of Fc receptors in HIV prevention and therapy |
Q55411165 | Uninfected Bystander Cells Impact the Measurement of HIV-Specific Antibody-Dependent Cellular Cytotoxicity Responses. |
Q91893991 | Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells |
Q60908099 | Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers |
Q40042419 | Vector order determines protection against pathogenic simian immunodeficiency virus infection in a triple component vaccine by balancing CD4+ and CD8+ T-cell responses |
Search more.